The overproliferation of cannabis strains following the institution of cannabis-complicit states within the US has led to uncertainty. Moreover, it ended in a shortage of clarity for the buyer at
the dispensary or seed banks.
As various states within the US are beginning cannabis programs one by one with little cooperation or standardization, entire countries do so efficiently at an equivalent pace. Around the world, about 2.25% of the population uses cannabis. Some of them even buy cheap auto flowering seeds and grow at the comfort of their homes.
The Medical And Recreational Cannabis Use
Cannabis is a multibillion-dollar global business. Lawful cannabis programs have already been implemented, no matter the international drug policy. The leading countries are;
- the UK
- the Czech Republic
- South Africa
Most of those countries regulate cannabis as a drug. Israel especially is a minimum of 10 years before the US institutes standardization within the production and extraction of cannabis for clinical trials resulting in patented drug products in line to realize consent from the US Food and Drug Administration (FDA) and entry into the promising direction of the market within the US. Most US Cannabis firms got to play catch up to realize market share. It is all starting with defining a large number of cannabis strains across the globe that is being grown.
The Cannabis Strain Database
The overproliferation of cannabis strains following the establishment of cannabis-complicit states within the US has led to confusion and resulted in a lack of transparency for the buyer at the dispensary. In Washington state alone, quite 39,000 cannabis strains are being grown.
Further confounding things for the recreational cannabis consumer and patient is that the sole reliance placed on tetrahydrocannabinol (THC) content determines the flower’s inherent value instead of taking everything off the pharmacologically active chem profile of the plant under consideration. Both state regulators and cannabis testing laboratories can help relieve the growing uncertainty. Regulators should institute broader chemical profiling, genotyping, and mandatory cannabis cultivar registration with specific criteria required before ever-growing the cultivar.
Moreover, people in cannabis testing laboratories that transcend simply quantifying cannabinoid potency. Furthermore, the quality assurance is in a unique position to demystify cannabis strains through expanded chemometrics, genotyping, and consumer education. Both approaches are aimed to offer cannabis consumers more confidence in what they are purchasing. On the upside, findings indicate that cannabis consumers are willing to pay a premium for genotyped, authenticated flowers.
Because the overwhelming majority of cannabis being grown within the US may be a Type I drug-type defined. From either indica or sativa seeds, it contains CBD and THC.
Green Waves From The East
Japanese officials have approved the medical CBD brand Epidiolex for clinical trials, marking the Japanese government’s primary time to approve such products. To be tightly controlled during a hospital environment, the trials are exempted from Japan’s Cannabis Control Act, which bans cannabis compounds generally.
Epidiolex, manufactured by UK-based GW Pharmaceutical, was approved by the U.S. Food and Drug Administration last year. Ministry of Health, Labor, and Welfare officials recently announced the trials during a gathering of the Okinawa-Northern Task Force, a search and development agency.
Epidiolex was crafted as a treatment for 2 sorts of childhood epilepsy. It’s the primary cannabis-derived prescription to realize federal approval within the US.
It was primarily developed to treat two severe sorts of epilepsy — Dravet Syndrome and Lennox-Gastaut Syndrome. In Japan, approximately 3,000 patients suffer from Dravet Syndrome, and a few 4,300 are afflicted with Lennox-Gastaut.